Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Menthol & Wintergreen Cream
Medicines register · Ireland

Menthol & Wintergreen Cream

Authorisation PA0206/022/001 · Ovelle Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Ovelle Limited (all products →)
Active substances
Turpentine oil, Oleoresin capsicum, Methyl salicylate, Levomenthol
Dosage form
Cream
Route of administration
Topical use
ATC code
M02AC
First authorised
01/09/1988
Prescription status
Product not subject to medical prescription
Supply
Supply through pharmacies only
Legal basis
Well-established use application (Article 10a of Directive No 2001/83/EC)

Turpentine oil: supply and approvals

3 authorised products on the HPRA list contain Turpentine oil. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 18 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Oleoresin capsicum: supply and approvals

1 authorised product on the HPRA list contains Oleoresin capsicum. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 18 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Methyl salicylate: supply and approvals

3 authorised products on the HPRA list contain Methyl salicylate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 18 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 38 years (since 1 September 1988). The HPRA list marks it as marketed in Ireland.

Other medicines with Turpentine oil in Ireland

2 other products on the HPRA list contain Turpentine oil, from 2 licence holders; 2 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Mentholatum Deep Heat CreamThe Mentholatum Company (Ireland) LimitedNational authorisation (PA)Marketed
Vicks Vaporub Inhalation Vapour, Ointment Levomenthol 2.75% w/wCamphor 5.00% w/wEucalyptus Oil 1.50% w/w Turpentine Oil 5.00% w/wWICK Pharma - Zweigniederlassung der Procter & Gamble GmbHNational authorisation (PA)Marketed

Other medicines with Oleoresin capsicum in Ireland

No other product on the HPRA list contains Oleoresin capsicum.

Other substances in ATC group M02AC

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 5 other active substances share the group M02AC with this product:

Racementhol (1) · Eucalyptus oil (1) · Ethyl salicylate (1) · Hydroxyethyl Salicylate (1) · Methyl nicotinate (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Ovelle Limited holds 14 products on the HPRA list, with 16 different active substances; 14 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.